Barclays analyst Balaji Prasad assigned a Buy rating to Tarsus Pharmaceuticals (TARS – Research Report) today and set a price target of $60.00. The company’s shares closed yesterday at $47.57.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback